insights_auto
Why is DMN down 5.11%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
€0.059
arrow_downward
-5.11%(-0.0032) 1D
Nov 20, 10:00:00 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€0.06
High
€0.06
Low
€0.06
Mkt. cap
135.12M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
42
Open
€0.06
High
€0.06
Low
€0.06
Mkt. cap
135.12M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
42
News stories
From web sources and news partners
TradingView
·
58 minutes ago
Yardeni Trims S&P 500 Year-End Forecast Again, Says Bear Market Is Unlikely
Traders Union
·
2 hours ago
A 12% S&P 500 drop matches UK and German markets going to zero, Howard Lindzon notes
Benzinga
·
1 hour ago
Dow Jones and S&P 500 Outlook: Top Stock Market Headlines and Data This Week
StoneX
·
2 days ago
S&P 500, Nasdaq 100 Drive into Correction Territory
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB
CEOUlf Hannelius
Employees42
Founded1984
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitediamyd.com